治療攝護腺肥大藥物之探討

The Pathology and Treatment of Benign Prostate Hyperplasia: Current concepts

高久理(Chiu-Li Kao) ； 曾于庭(Yu-Ting Tseng) ； 林維楨(Wei-Chen Lin) ； 劉棋銘(Chi-Ming Liu)

《慈惠學報》 13期 (2017/12) Pp. 78-88

https://doi.org/10.6202/THJ.201712_(13).0006

摘要

攝護腺肥大普遍發生於老年族群。攝護腺肥大使病患產生下泌尿道症候群。年齡、荷爾蒙、生長因子、發炎和生活方式會影響攝護腺肥大的發展。臨床上α-腎上腺受體拮抗劑和5α-還原酶抑製劑用於治療攝護腺肥大之症狀與排尿障礙。在本文中，我們將進一步探討藥物於治療攝護腺肥大之分子藥理機制與攝護腺肥大治療新趨勢。

關鍵字

攝護腺肥大 ； α-腎上腺受體拮抗劑 ； 5α-還原酶抑製劑

並列摘要

Benign prostate hyperplasia (BPH) is highly prevalent in the aging population, particularly in men. Prostate enlargement leads to male lower urinary tract symptoms (LUTS). Several factors cause the development of benign prostate hyperplasia including age, hormones, growth factors, inflammation, and lifestyle. In clinical setting, α -adrenergic antagonists and 5α-reductase inhibitors are used for the treatment of BPH. In this article, we will discuss the molecule mechanisms of action of drug and new concepts in the treatment of BPH.

並列關鍵字

benign prostate hyperplasia ； α-adrenergic antagonist ； 5α-reductase inhibitor

參考文獻

Batty, M., Pugh, R., Rathinam, I., Simmonds, J., Walker, E., Forbes, A., . . .Chess‐Williams, R. (2016). The Role of alpha1‐Adrenoceptor Antagonists inthe Treatment of Prostate and Other Cancers. Int J Mol Sci, 17(8). doi:10.3390/ijms17081339

Burnett, A. L., & Wein, A. J. (2006). Benign prostatic hyperplasia in primary care: whatyou need to know. J Urol, 175(3 Pt 2), S19‐24. doi:10.1016/S0022‐5347(05)00310‐1

Calmasini, F. B., Silva, F. H., Alexandre, E. C., Rodrigues, R. L., Barbosa, A. P., Ferrucci,D. L., . . . Antunes, E. (2017). Implication of Rho‐kinase and soluble guanylylcyclase enzymes in prostate smooth muscle dysfunction in middle‐aged rats.Neurourol Urodyn, 36(3), 589‐596. doi: 10.1002/nau.22990

Chughtai, B., Thomas, D., & Kaplan, S. (2016). alpha‐Blockers, 5‐alpha‐ReductaseInhibitors, Acetylcholine, beta3 Agonists, and Phosphodiesterase‐5s inMedical Management of Lower Urinary Tract Symptoms/Benign ProstaticHyperplasia: How Much Do the Different Formulations Actually Matter in theClasses? Urol Clin North Am, 43(3), 351‐356. doi: 10.1016/j.ucl.2016.04.013

Dimitropoulos, K., & Gravas, S. (2015). Solifenacin/tamsulosin fixed‐dosecombination therapy to treat lower urinary tract symptoms in patients withbenign prostatic hyperplasia. Drug Des Devel Ther, 9, 1707‐1716. doi:10.2147/DDDT.S53184